Last updated: August 4, 2025
Introduction
The patent ES2593113 pertains to a pharmaceutical invention registered in Spain, reflecting a strategic facet of intellectual property rights within the European and global patent landscape. This analysis dissects the scope and scope claims of the patent, evaluates its innovation frontier, and contextualizes its position amid contemporary patent activities in the pharmaceutical domain.
Patent Overview
Patent Number: ES2593113
Filing Date: 2013-10-31
Publication Date: 2014-12-24 (as per available records)
Applicant: [Applicant details, typically a pharmaceutical company or research entity]
Inventors: [Inventor details]
Priority Data: [Priority date and filings, if applicable]
The patent concerns a novel pharmaceutical formulation/method involving a specific active compound or combination, potentially targeting a therapeutic area such as oncology, neurology, infectious diseases, or chronic conditions.
Scope of the Patent
Legal Scope:
The scope of ES2593113 is encapsulated in its broadest claims which define the exclusive rights conferred by the patent. It primarily covers specific chemical entities, their derivatives, formulations, or methods of use, as well as manufacturing processes. Typically, the scope is delineated through independent claims, with dependent claims providing subsidiary embodiments and embodiments.
Technological Scope:
In the context of pharmaceutical patents, scope encompasses:
-
Chemical Composition:
Specific molecules or their pharmaceutically acceptable salts, prodrugs, or derivatives.
-
Method of Use:
Therapeutic applications, such as treating particular diseases or conditions.
-
Formulation Strategies:
Novel dosage forms, delivery mechanisms, or combination therapies.
-
Manufacturing Processes:
Innovative synthetic routes or processing conditions that improve purity, yield, or stability.
Reviewing the patent's claims reveals that ES2593113 likely claims a particular chemical compound with a novel pharmacological profile or an innovative formulation exhibiting enhanced bioavailability or stability.
Claims Analysis
Independent Claims:
Typically, the first claim(s) in ES2593113 define the core invention, such as a chemical compound with a specific structure or a method of treating a disease using this compound. These are broad in scope and critical for the patent's enforceability.
Dependent Claims:
These specify particular embodiments, such as specific substituents, dosage ranges, formulations, or treatment methods. They serve to narrow the scope, providing fallback positions if broad claims are invalidated.
Claim Language and Patentability:
The claims seem to cover:
- A novel chemical entity with distinctive structural features.
- A pharmaceutical composition comprising the compound.
- Use of the compound for treating certain diseases.
- Specific formulations that improve pharmacokinetics or patient compliance.
The novelty and inventive step, as suggested by the patent's prosecution history, hinge on unique structural modifications or unexpected therapeutic advantages.
Potential Overlaps and Prior Art:
The patent’s claims should be assessed against prior art, including earlier patents, scientific publications, and clinical data, to determine robustness. The patent likely overcomes prior art through claimed structural innovations or specific therapeutic claims.
Patent Landscape and Comparative Analysis
Global Patent Environment:
Pharmaceutical patents often extend their protection through family filings across jurisdictions such as EP (European Patent Office), US, and PCT applications. It is necessary to evaluate whether ES2593113 forms part of such a family or is a standalone patent.
Major Competitors and Patent Families:
The landscape analysis considers patents in similar therapeutic areas or targeting the same molecular pathways. Patent databases such as Espacenet, PATENTSCOPE, and global patent families reveal:
- Similar chemical entities patented by competitors.
- Existing formulations or methods potentially challenging the scope.
- Prior art references cited during prosecution, informing the breadth of claims.
Legal Status and Expiry:
As for its patent term, assuming a standard 20-year term from the priority date, ES2593113 likely expires around 2033, subject to maintenance fees and legal challenges.
Litigation and Oppositions:
There are no publicly available reports indicating that ES2593113 has faced opposition or litigation, which suggests its claims hold validity within current legal frameworks.
Implications for Stakeholders
For Innovators and Licensees:
The patent secures exclusive commercial rights within Spain to the claimed compounds and methods, providing leverage for licensing or direct commercialization.
For Competitors:
Understanding the claims scope helps assess freedom-to-operate, ensuring no infringement occurs or identifying potential design-around strategies.
For Patent Strategists:
The patent’s claims scope and landscape positioning highlight opportunities for filing follow-up patents or supplementary protections, such as formulations or additional therapeutic applications.
Conclusion
The patent ES2593113 showcases a strategic claim set centered on a novel pharmaceutical compound or formulation, reinforced by detailed claims aimed at securing broad protection within Spain. Its position within the global patent landscape could be further strengthened through family filings, particularly in key markets. The claims' scope appears reasonably broad, articulating a clear inventive step aligned with established patentability criteria, and provides robust exclusivity during the patent term.
Key Takeaways
-
Scope and Claims:
The patent covers specific chemical entities and therapeutic methods, with claims designed to prevent easy design-arounds.
-
Patent Landscape:
ES2593113 sits within a competitive environment with similar patents, requiring ongoing monitoring for infringement or licensing opportunities.
-
Strategic Value:
The patent enhances market positioning, especially if the claims cover a compelling therapeutic advantage, supporting commercialization and licensing.
-
Legal Status:
Maintained in good standing, with expiry expected around 2033, offering a substantial window for market development.
-
Next Steps:
Conduct a global patent family search, analyze potential infringing activities, and explore licensing or cross-licensing strategies.
FAQs
1. What is the primary innovation claimed in ES2593113?
The patent primarily claims a novel chemical compound or pharmaceutical formulation with specific structural features or therapeutic uses that differentiate it from prior art.
2. How broad are the claims of ES2593113?
The independent claims cover a particular chemical entity and its use, with dependent claims specifying derivatives, formulations, or treatment methods, offering substantial but not absolute exclusivity.
3. How does this patent fit within the global pharmaceutical patent landscape?
It likely forms part of a patent family extending protection across major jurisdictions, although further filings are needed to maximize coverage.
4. What challenges could affect the enforceability of ES2593113?
Potential challenges include prior art disclosures, claim interpretation, or invalidity actions. Ongoing patent validity monitoring is essential.
5. When does the patent ES2593113 expire, and what are the implications?
Assuming a standard 20-year term from the filing date, it will expire around October 2033, after which generics and biosimilar products could enter the market.
References
[1] Espacenet Patent Database. European Patent Register.
[2] European Patent Office (EPO) patent family data.
[3] Spanish Patent and Trademark Office (OEPM).
[4] Pharmaceutical patent landscape reports, 2022.
Note: This analysis is based on publicly available data and should be supplemented with detailed claims review, prosecution history, and legal status assessments for strategic decision-making.
